Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC)

Lorenzo Gerratana, Qiang Zhang, Ami Naimish Shah, Andrew Adam Davis, Youbin Zhang, Firas Wehbe, Wenan Qiang, Lisa Flaum, Brian Steven Finkelman, William John Gradishar, Leonidas C. Platanias, Amir Behdad, Massimo Cristofanilli*

*Corresponding author for this work

Research output: Contribution to journalReview article


Circulating tumor DNA (ctDNA) is gaining momentum as sensitive diagnostic tool for advanced disease characterization because of its ability both to capture the tumor's heterogeneity and its dynamic adaptations. However, the consistency between all the available platforms is still debated. The aim of the study was to explore the performance of the novel diagnostic NGS platform PredicinePLUS™ and to compare its results with the clinically available Guardant360™ platform for possible analytical inconsistencies. The study suggests that PredicinePLUS™ NGS platform can detect genomic alterations and measure allele frequency in samples of MBC patients and confirmed that different NGS platforms could be potentially compared provided that certain sample management and analytical requirements are met.

Original languageEnglish (US)
Article number102856
JournalCritical Reviews in Oncology/Hematology
StatePublished - Jan 2020



  • Circulating tumor DNA
  • Clinical utility
  • Next generation sequencing
  • Precision medicine

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this